Mycobacterium tuberculosis isolates from Rio de Janeiro reveal unusually low correlation between pyrazinamide resistance and mutations in the pncA gene

Infection, Genetics and Evolution

Volumn 19, Issue , 2013, Pages 1-6

  Bhuju, Sabin ^a   Fonseca, Leila de Souza ^b   Marsico, Anna Grazia ^b   de Oliveira Vieira, Gisele Betzler ^b   Sobral, Luciana Fonseca ^b   Stehr, Matthias ^a   Singh, Mahavir ^a,c   Saad, Maria Helena Féres ^d  

^a HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c LIONEX DIAGNOSTICS AND THERAPEUTICS GMBH   (Germany)

^d INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Mycobacterium tuberculosis; PncA gene mutation; Pyrazinamide; Resistance; Tuberculosis

Indexed keywords

BACTERIAL DNA; BACTERIAL ENZYME; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDASE; PYRAZINAMIDE; PYRAZINOIC ACID; RIBOSOMAL PROTEIN S1; RIBOSOME PROTEIN; RIFAMPICIN; STREPTOMYCIN; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; BINDING SITE; BRAZIL; CONTROLLED STUDY; ENDEMIC DISEASE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; GENE DELETION; GENE INSERTION; GENE MUTATION; GENETIC ASSOCIATION; MULTIDRUG RESISTANCE; MUTATIONAL ANALYSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; PNCA GENE; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RPSA GENE; SHORT TANDEM REPEAT;

MYCOBACTERIUM TUBERCULOSIS; PNCA GENE MUTATION; PYRAZINAMIDE; RESISTANCE; TUBERCULOSIS;

AMIDOHYDROLASES; ANTI-BACTERIAL AGENTS; BRAZIL; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; HUMANS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; TUBERCULOSIS;

EID: 84880272570     PISSN: 15671348     EISSN: 15677257     Source Type: Journal    
DOI: 10.1016/j.meegid.2013.06.008     Document Type: Article

References (46)

1. Alexander D.C., Ma J.H., Guthrie J.L., Blair J., Chedore P., Jamieson F.B. Gene sequencing for routine verification of pyrazinamide resistance in Mycobacterium tuberculosis: a role for pncA but not rpsA. J. Clin. Microbiol. 2012, 50:3726-3728.
2. Barco P., Cardoso R.F., Hirata R.D., Leite C.Q., Pandolfi J.R., Sato D.N., Shikama M.L., de Melo F.F., Mamizuka E.M., Campanerut P.A., Hirata M.H. PncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis clinical isolates from the southeast region of Brazil. J. Antimicrob. Chemother. 2006, 58:930-935.
3. Bishop K.S., Blumberg L., Trollip A.P., Smith A.N., Roux L., York D.F., Kiepiela P. Characterisation of the pncA gene in Mycobacterium tuberculosis isolates from Gauteng, South Africa. Int. J. Tuberc. Lung Dis. 2001, 5:952-957.
4. Blanchard J.S. Molecular mechanisms of drug resistance in Mycobacterium tuberculosis. Annu. Rev. Biochem. 1996, 65:215-239.
5. Butler W.R., Kilburn J.O. Susceptibility of Mycobacterium tuberculosis to pyrazinamide and its relationship to pyrazinamidase activity. Antimicrob. Agents Chemother. 1983, 24:600-601.
6. Canetti G., Fox W., Khomenko A., Mahler H.T., Menon N.K., Mitchison D.A., Rist N., Smelev N.A. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull. World Health Organ. 1969, 41:21-43.
7. Chan R.C., Hui M., Chan E.W., Au T.K., Chin M.L., Yip C.K., AuYeang C.K., Yeung C.Y., Kam K.M., Yip P.C., Cheng A.F. Genetic and phenotypic characterization of drug-resistant Mycobacterium tuberculosis isolates in Hong Kong. J. Antimicrob. Chemother. 2007, 59:866-873.
8. Chang K.C., Yew W.W., Zhang Y. Pyrazinamide susceptibility testing in Mycobacterium tuberculosis: a systematic review with meta-analyses. Antimicrob. Agents Chemother. 2011, 55:4499-4505.
9. Chiu Y.C., Huang S.F., Yu K.W., Lee Y.C., Feng J.Y., Su W.J. Characteristics of pncA mutations in multidrug-resistant tuberculosis in Taiwan. BMC Infect. Dis. 2011, 11:240-246.
10. Dormandy J., Somoskovi A., Kreiswirth B.N., Driscoll J.R., Ashkin D., Salfinger M. Discrepant results between pyrazinamide susceptibility testing by the reference BACTEC 460TB method and pncA DNA sequencing in patients infected with multidrug-resistant W-Beijing Mycobacterium tuberculosis strains. Chest 2007, 131:497-501.
11. Fonseca L.S., Marsico A.G., Vieira G.B., Duarte R.S., Saad M.H., Mello F.C. Correlation between resistance to pyrazinamide and resistance to other antituberculosis drugs in Mycobacterium tuberculosis strains isolated at a referral hospital. J. Bras. Pneumol. 2012, 38:630-633.
12. Hewlett D., Horn D.L., Alfalla C. Drug-resistant tuberculosis: inconsistent results of pyrazinamide susceptibility testing. JAMA 1995, 273:916-917.
13. Hirano K., Takahashi M., Kazumi Y., Fukasawa Y., Abe C. Mutation in pncA is a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis. Tuber. Lung Dis. 1997, 78:117-122.
14. Hou L., Osei-Hyiaman D., Zhang Z., Wang B., Yang A., Kano K. Molecular characterization of pncA gene mutations in Mycobacterium tuberculosis clinical isolates from China. Epidemiol. Infect. 2000, 124:227-232.
15. Huang T.S., Lee S.S., Tu H.Z., Huang W.K., Chen Y.S., Huang C.K., Wann S.R., Lin H.H., Liu Y.C. Correlation between pyrazinamide activity and pncA mutations in Mycobacterium tuberculosis isolates in Taiwan. Antimicrob. Agents Chemother. 2003, 47:3672-3673.
16. Jonmalung J., Prammananan T., Leechawengwongs M., Chaiprasert A. Surveillance of pyrazinamide susceptibility among multidrug-resistant Mycobacterium tuberculosis isolates from Siriraj Hospital, Thailand. BMC Microbiol. 2010, 10:223-228.
17. Kim H.J., Kwak H.K., Lee J., Yun Y.J., Lee J.S., Lee M.S., Min S.Y., Park S.K., Kang H.S., Maeng Y.H., Kim S.Y., Kook Y.H., Kim Y.R., Lee K.H. Patterns of pncA mutations in drug-resistant Mycobacterium tuberculosis isolated from patients in South Korea. Int. J. Tuberc. Lung Dis. 2012, 16:98-103.
18. Lee K.W., Lee J.M., Jung K.S. Characterization of pncA mutations of pyrazinamide-resistant Mycobacterium tuberculosis in Korea. J. Korean Med. Sci. 2001, 16:537-543.
19. Lemaitre N., Sougakoff W., Truffot-Pernot C., Jarlier V. Characterization of new mutations in pyrazinamide-resistant strains of Mycobacterium tuberculosis and identification of conserved regions important for the catalytic activity of the pyrazinamidase PncA. Antimicrob. Agents Chemother. 1999, 43:1761-1763.
20. Louw G.E., Warren R.M., Donald P.R., Murray M.B., Bosman M., Van Helden P.D., Young D.B., Victor T.C. Frequency and implications of pyrazinamide resistance in managing previously treated tuberculosis patients. Int. J. Tuberc. Lung Dis. 2006, 10:802-807.
21. Mc Dermott W., Tompsett R. Activation of pyrazinamide and nicotinamide in acidic environments in vitro. Am. Rev. Tuberc. 1954, 70:748-754.
22. McClatchy J.K., Tsang A.Y., Cernich M.S. Use of pyrazinamidase activity on Mycobacterium tuberculosis as a rapid method for determination of pyrazinamide susceptibility. Antimicrob. Agents Chemother. 1981, 20:556-557.
23. Minime-Lingoupou F., Pierre-Audigier C., Kassa-Kelembho E., Barilone N., Zandanga G., Rauzier J., Cadet-Daniel V., Le Faou A., Gicquel B. Rapid identification of multidrug-resistant tuberculosis isolates in treatment failure or relapse patients in Bangui, Central African Republic. Int. J. Tuberc. Lung Dis. 2010, 14:782-785.
24. Miyagi C., Yamane N., Yogesh B., Ano H., Takashima T. Genetic and phenotypic characterization of pyrazinamide-resistant Mycobacterium tuberculosis complex isolates in Japan. Diagn. Microbiol. Infect. Dis. 2004, 48:111-116.
25. Mphahlele M., Syre H., Valvatne H., Stavrum R., Mannsåker T., Muthivhi T., Weyer K., Fourie P.B., Grewal H.M. Pyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolates. J. Clin. Microbiol. 2008, 46:3459-3464.
26. Ngo S.C., Zimhony O., Chung W.J., Sayahi H., Jacobs W.R., Welch J.T. Inhibition of isolated Mycobacterium tuberculosis fatty acid synthase I by pyrazinamide analogs. Antimicrob. Agents Chemother. 2007, 51:2430-2435.
27. Pandey S., Newton S., Upton A., Roberts S., Drinkovic D. Characterisation of pncA mutations in clinical Mycobacterium tuberculosis isolates in New Zealand. Pathology 2009, 41:582-584.
28. Petrella S., Gelus-Ziental N., Maudry A., Laurans C., Boudjelloul R., Sougakoff W. Crystal structure of the pyrazinamidase of Mycobacterium tuberculosis: Insights into natural and acquired resistance to pyrazinamide. PLoS One 2011, 6:e15785.
29. Raynaud C., Laneelle M.A., Senaratne R.H., Draper P., Laneelle G., Daffe M. Mechanisms of pyrazinamide resistance in mycobacteria: importance of lack of uptake in addition to lack of pyrazinamidase activity. Microbiology 1999, 145:1359-1367.
30. Rodrigues V.F., Telles M.A., Ribeiro M.O., Cafrune P.I., Rossetti M.L., Zaha A. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis in Brazil. Antimicrob. Agents Chemother. 2005, 49:444-446.
31. Sandgren A., Strong M., Muthukrishnan P., Weiner B.K., Church G.M., Murray M.B. Tuberculosis drug resistance mutation database. PLoS Med. 2009, 6(2):e1000002.
32. Scorpio A., Lindholm-Levy P., Heifets L., Gilman R., Siddiqi S., Cynamon M., Zhang Y. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 1997, 41:540-543.
33. Shenai S., Rodrigues C., Sadani M., Sukhadia N., Mehta A. Comparison of phenotypic and genotypic methods for pyrazinamide susceptibility testing. Indian J. Tuberc. 2009, 56:82-90.
34. Shi W., Zhang X., Jiang X., Yuan H., Lee J.S., Barry C.E., Wang H., Zhang W., Zhang Y. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science 2011, 333:1630-1632.
35. Simons S.O., van Ingen J., van der Laan T., Mulder A., Dekhuijzen P.N., Boeree M.J., van Soolingen D. Validation of pncA gene sequencing in combination with the mycobacterial growth indicator tube method to test susceptibility of Mycobacterium tuberculosis to pyrazinamide. J. Clin. Microbiol. 2012, 50:428-434.
36. Singh P., Wesley C., Jadaun G.P., Malonia S.K., Das R., Upadhyay P., Faujdar J., Sharma P., Gupta P., Mishra A.K., Singh K., Chauhan D.S., Sharma V.D., Gupta U.D., Venkatesan K., Katoch V.M. Comparative evaluation of Löwenstein-Jensen proportion method, BacT/ALERT 3D system, and enzymatic pyrazinamidase assay for pyrazinamide susceptibility testing of Mycobacterium tuberculosis. J. Clin. Microbiol. 2007, 45:76-80.
37. Somoskovi A., Dormandy J., Parsons L.M., Kaswa M., Goh K.S., Rastogi N., Salfinger M. Sequencing of the pncA gene in members of the Mycobacterium tuberculosis complex has important diagnostic applications: Identification of a species-specific pncA mutation in "Mycobacterium canettii" and the reliable and rapid predictor of pyrazinamide resistance. J. Clin. Microbiol. 2007, 45:595-599.
38. Sreevatsan S., Pan X., Zhang Y., Kreiswirth B.N., Musser J.M. Mutations associated with pyrazinamide resistance in pncA of Mycobacterium tuberculosis complex organisms. Antimicrob. Agents Chemother. 1997, 41:636-640.
39. Staden R., Beal K.F., Bonfield J.K. The Staden package, 1998. Methods Mol. Biol. 2000, 132:115-130.
40. Tarshis M.S., Weed W.A. Lack of significant in vitro sensitivity of Mycobacterium tuberculosis to pyrazinamide on three different solid media. Am. Rev. Tuberc. 1953, 67:391-395.
41. Van Embden J.D.A., Cave M.D., Crawford J.T., Dale J.W., Eisenach K.D. Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recomendations for a standirzed methodology. J. Clin. Microbiol. 1993, 31(2):406-409.
42. Wayne L.G. Simple pyrazinamidase and urease tests for routine identification of mycobacteria. Am. Rev. Respir. Dis. 1974, 109:147-151.
43. WHO, World Health Organization. The Global tuberculosis Report 2012.
44. Zhang Y., Mitchison D. The curious characteristics of pyrazinamide: a review. Int. J. Tuberc. Lung Dis. 2003, 7:6-21.
45. Zhang Y., Yew W.W. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 2009, 13:1320-1330.
46. Zhang Y., Permar S., Sun Z. Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J. Med. Microbiol. 2002, 51:42-49.